Patient info Open main menu

tolterodine tartrate Tolterodine tartrate 2mg/5ml Oral Suspension – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
2 mg/5 ml (400 microgram/ml)
Contains active substance:

Patient leaflet - Tolterodine Tartrate 2 mg/5 ml oral suspension

1. What Tolterodine tartrate is and what it is used for

The active substance in Tolterodine tartrate is tolterodine. Tolterodine belongs to a class of medicinal products called antimuscarinics. Tolterodine tartrate is used for the treatment of the symptoms of overactive bladder syndrome.

2. What you need to know before you take Tolterodine tartrate

Do not take Tolterodine tartrate if:

  • You are allergic (hypersensitive) to tolterodine or any of

    the other ingredients in Tolterodine tartrate (listed in section 6).

  • You are unable to pass urine from the bladder (urinary retention)
  • You have an uncontrolled narrow-angle glaucoma (high pressure in the eyes with loss of eyesight that is not

    being adequately treated)

  • You suffer from myasthenia gravis (excessive weakness

    of the muscles)

  • You suffer from severe ulcerative colitis (ulceration and inflammation of the colon)
  • You suffer from a toxic megacolon (acute dilatation of

    the colon).

Warnings and precautions

Talk to your doctor or pharmacist before you take Tolterodine tartrate if:

  • You have difficulties in passing urine and/or a poor

    stream of urine

  • You have a gastro-intestinal disease that affects the passage and/or digestion of food
  • You suffer from kidney problems (renal insufficiency)
  • You have a liver condition
  • You suffer from neuronal disorders that affect your blood pressure, bowel or sexual function (any neuropathy of

    the autonomic nervous system)

  • You have a hiatal hernia (herniation of an abdominal

    organ)

  • You ever experience decreased bowel movements or

    suffer from severe constipation (decreased gastro-intestinal motility)

  • You have abnormally low levels of potassium

    (hypokalaemia), calcium (hypocalcaemia) or magnesium (hypomagnesaemia) in your blood

  • You have a heart condition such as:

    • an abnormal heart tracing (ECG);
    • a slow heart rate (bradycardia);
    • relevant pre-existing cardiac diseases such as;

      • cardiomyopathy (weak heart muscle);
      • myocardial ischaemia (reduced blood flow to the heart);
      • arrhythmia (irregular heartbeat); and
      • heart failure

Other medicines and Tolterodine tartrate

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines as tolterodine may interact with other medicinal products.

It is not recommended to use tolterodine in combination with

  • some antibiotics (containing e.g. erythromycin, clarithromycin)
  • medicinal products used for the treatment of fungal infections (containing e.g. ketoconazole, itraconazole);
  • medicinal products used for the treatment of HIV

    Tolterodine tartrate should be used with caution when taken in combination with:

    • medicines that affect the passage of food (containing e. g. metoclopramide and cisapride)
    • medicines for the treatment of irregular heartbeat

      (containing e.g. amiodarone, sotalol, quinidine, procainamide)

    • other medicines with a similar mode of action to tolterodine (antimuscarinic properties) or medicines with an opposite mode of action to tolterodine (cholinergic properties). Ask your doctor if you are unsure.

Inform your doctor and pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Tolterodine tartrate with food and drink

Tolterodine tartrate can be taken before, after or during a meal.

Pregnancy and breast-feeding

Pregnancy

You should not use Tolterodine tartrate when you are pregnant. Tell your doctor immediately if you are pregnant, think you are pregnant or are planning to become pregnant.

Breast-feeding

It is not known if tolterodine, the active substance of Tolterodine tartrate, is excreted in the mother’s breast milk.

Breast-feeding is not recommended during administration of Tolterodine tartrate

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

Tolterodine tartrate may make you feel dizzy, tired or affect your sight; your ability to drive or operate machinery may be affected.

Tolterodine tartrate contains methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium, benzyl alcohol and benzoic acid

Methyl parahydroxybenzoate, propyl parahydroxybenzoate: May cause allergic reactions (possibly delayed). Sodium: This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’. Benzoic acid (E210): This medicine contains 0.011 mg benzoic acid in each ml.

Benzyl alcohol (E1519): This medicine contains 0.02 mg benzyl alcohol in each ml. Benzyl alcohol may cause allergic reactions.

3. How to take Tolterodine tartrate

Dosage

Always take Tolterodine tartrate exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The usual dose is 2 mg (5 ml) twice daily, except for patients who have a kidney or a liver condition or troublesome side effects in which case your doctor may reduce your dose to 1 mg (2.5 ml) twice daily.

Tolterodine tartrate is not recommended for children.

Tolterodine tartrate is for oral use.

Duration of treatment

Your doctor will tell you how long your treatment with Tolterodine tartrate will last. Do not stop treatment early because you do not see an immediate effect. Your bladder will need some time to adapt. Finish the course of Toltero-dine tartrate prescribed by your doctor. If you have not noticed any effect by then, talk to your doctor.

The benefit of the treatment should be re-evaluated after 2 or 3 months.

Always consult your doctor if you are thinking of stopping the treatment.

Route and Method of administration:

  • This medicinal product must be taken orally.
  • Use the 2.5-5 ml double-ended spoon supplied in the pack to measure the required dose (see figure below).
  • Shake well before use for at least 10 seconds.
  • Wash the spoon with clean water after taking every dose.

    2.5-5 ml double-ended spoon

    TURN OVER 2.5ml 5ml

    (Small end) (Large end) If you have taken more Tolterodine tartrate than you should:

If you or somebody else takes too much Tolterodine tartrate, contact your doctor or pharmacist immediately.

If you forget to take Tolterodine tartrate

If you forget to take a dose at the usual time, take it as soon as you remember unless it is almost time for your next dose. In that case, omit the forgotten dose and follow the normal dose schedule.

Do not take a double dose to make up for a forgotten one.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You should see your doctor immediately or go to the Accident and Emergency department if you experience symptoms of angioedema, such as

  • swollen face, tongue or pharynx
  • difficulty to swallow
  • hives and difficulty in breathing

You should also seek medical attention if you experience a hypersensitivity reaction (for example itching, rash, hives, difficulty breathing). This occurs uncommonly (occurs in less than 1 in 100 patients).

Tell your doctor immediately or go to the Accident and Emergency department if you notice any of the following:

  • chest pain, difficulty breathing or getting tired easily

    (even at rest), difficulty breathing at night, swelling of the legs.

These may be symptoms of heart failure. This occurs uncommonly (occurs in less than 1 in 100 patients).

The following side effects have been observed during treatment with tolterodine with the following frequencies.

Very common side effects (occurs in more than 1 in 10 patients) are:

  • Dry mouth
  • Headache

Common side effects (occurs in less than 1 in 10 patients) are:

  • Bronchitis
  • Dizziness, sleepiness, sensation of pins and needles in

    the fingers and toes

  • Dry eyes, blurred vision
  • Vertigo
  • Palpitations
  • Difficulty in digestion (dyspepsia), constipation,

    abdominal pain, excessive amounts of air or gases in the stomach or the intestine, vomiting

  • Dry skin
  • Painful or difficult urination, inability to empty the bladder
  • Tiredness, chest pain, extra fluid in the body causing

    swelling (e.g. in the ankles)

  • Increased weight
  • Diarrhoea

Uncommon side effects (occurs in less than 1 in 100 patients) are:

  • Allergic reactions
  • Nervousness
  • Increased heart rate, heart failure, irregular heartbeat
  • Heart burn
  • Memory impairment

Additional reactions reported include severe allergic reactions, confusion, hallucinations, flushed skin, angioedema, and disorientation. There have also been reports of worsening symptoms of dementia in patients being treated for dementia.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website:

www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Tolterodine tartrate

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is

    stated on the carton and bottle label after ‘EXP’. The expiry date refers to the last day of that month.

  • Do not store above 25°C.
  • Do not refrigerate or freeze.
  • Store in the original package to protect from light

    • Do not use this medicine if you notice that the suspension becomes discoloured or shows any signs of deterioration. Seek the advice of your pharmacist.
    • Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Tolterodine tartrate contains

The active substance is tolterodine tartrate.

Each 5 ml of oral suspension contains 2 mg of tolterodine tartrate, equivalent to 1.37 mg tolterodine.

The other ingredients are methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), simethicone emulsion 30% (contains propylene glycol (E1520) & benzoic acid (E210)), microcrystalline cellulose (E460), sucralose (E955), cherry flavour (contains propylene glycol (E1520) & benzyl alcohol (E1519)), silica colloidal anhydrous (E551), citric acid monohydrate (E330), sodium citrate (E331) and purified water.

What Tolterodine tartrate looks like and contents of the pack

Tolterodine tartrate is a white to off-white oral suspension in a glass bottle. Each pack contains one bottle containing 150 ml oral suspension and a 2.5-5 ml double ended spoon.

Marketing Authorisation Holder and Manufacturer:

Syri Limited t/a SyriMed

Unit 4, Bradfield Road,

Ruislip, Middlesex,

HA4 0NU, UK.

If this leaflet is hard to see or read, please call +44 (0) 208 515 3700 for help.

This leaflet was last revised in 12/2025.

PIL/UK/MFG162/02/v1

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 39307/0148

Last revision stated in the text: December 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Tolterodine Tartrate 2 mg/5 ml oral suspension

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Tolterodine
Strength 2 mg/5 ml (400 microgram/ml)
Pharmaceutical form Oral suspension
White to off-white suspension
How is it taken Oral
Excipients Methyl parahydroxybenzoate (E218), Propyl parahydroxybenzoate (E216), Simethicone emulsion 30% (contains benzoic acid (E210)) Microcrystalline Cellulose (E460), Sucralose (E955), Cherry flavour (contains propylene glycol (E1520) and benzyl alcohol (E1519)), Silica colloidal anhydrous (E551), Citric acid monohydrate (E330), Sodium citrate (E331), Purified water
Pack sizes 150 ml
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 2 years
Discard 60 days after first opening
Storage Do not store above 25 .
Do not refrigerate or freeze.
Store in the original package to protect from light.
Drug group (ATC) Urinary antispasmodics
  1. G Genito urinary system and sex hormones
    1. G04 Urologicals
      1. G04B Urologicals
        1. G04BD Drugs for urinary frequency and incontinence
          1. G04BD07 tolterodine
Marketing authorisation PL 39307/0148 (first authorised 16 January 2026)
Marketing authorisation holder Syri Limited t/a SyriMed
Codes GTIN 5055935105714 · BNF 07040200

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.